{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:03:28Z","timestamp":1793322208928,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.josat.2024.209382","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T17:36:45Z","timestamp":1714066605000},"page":"209382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0380-4202","authenticated-orcid":false,"given":"Taylor J.","family":"Paiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-1776","authenticated-orcid":false,"given":"Rachel S.","family":"Wightman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"St. John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam Z.","family":"Nitenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collette","family":"Onyejekwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Hallowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.josat.2024.209382_bb0005","first-page":"4598","article-title":"Physician\u2019s burnout during the COVID-19 pandemic: A systematic review and meta-analysis","volume":"20","author":"Alkhamees","year":"2023","journal-title":"International Journal of Environmental Research"},{"key":"10.1016\/j.josat.2024.209382_bb0010","unstructured":"Bestsennyy O., Gilbert G., Harris A., & Rost J. (2021). Telehealth: A quarter-trillion-dollar post-covid-19 reality? https:\/\/www.mckinsey.com\/industries\/healthcare\/our-insights\/telehealth-a-quarter-trillion-dollar-post-covid-19-reality."},{"issue":"9","key":"10.1016\/j.josat.2024.209382_bb0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patient with opioid use disorder in the era of fentanyl","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209382_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108283","article-title":"Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island","volume":"124","author":"Clark","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209382_bb0025","series-title":"Medications for opioid use disorder save lives","author":"Committee on Medication-Assisted Treatment for Opioid Use Disorder","year":"2019"},{"key":"10.1016\/j.josat.2024.209382_bb3005","unstructured":"Consolidated Appropriations Act, H.R. 2617, 117th Congress (2023). https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/2617."},{"key":"10.1016\/j.josat.2024.209382_bb0030","unstructured":"Federation of State Medical Boards. (2023). Model policy on data 2000 and treatment of opioid addiction in the medical office. https:\/\/www.fsmb.org\/siteassets\/advocacy\/policies\/model-policy-on-data-2000-and-treatment-of-opioid-addiction-in-the-medical-office.pdf."},{"issue":"4","key":"10.1016\/j.josat.2024.209382_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209382_bb0040","unstructured":"Goldstein A. (2023). Nearly 4 million in U.S. cut from Medicaid, most for paperwork reasons. https:\/\/www.washingtonpost.com\/health\/2023\/07\/28\/medicaid-unwinding-pandemic\/."},{"issue":"5","key":"10.1016\/j.josat.2024.209382_bb0045","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ADM.0000000000001189","article-title":"Evidence on buprenorphine dose limits: A review","volume":"17","author":"Grande","year":"2023","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2024.209382_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109680","article-title":"Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population","volume":"241","author":"Hallowell","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2024.209382_bb0055","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.2105\/AJPH.2021.306395","article-title":"History of methadone and buprenorphine opioid agonist therapy among people who died of an accidental opioid-involved overdose: Rhode Island, January 1, 2018\u2013June 30, 2020","volume":"111","author":"Hallowell","year":"2021","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.josat.2024.209382_bb0060","series-title":"Why 41% of patients have skipped care during COVID-19 pandemic","author":"Henry","year":"2023"},{"issue":"1","key":"10.1016\/j.josat.2024.209382_bb3000","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11606-021-07174-w","article-title":"Initiating opioid use disorder medication via telemedicine during COVID-19: Implications for proposed reforms to the Ryan Haight Act","volume":"37","author":"Huskamp","year":"2022","journal-title":"Journal of General Internal Medicine"},{"issue":"5","key":"10.1016\/j.josat.2024.209382_bb0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.12419","article-title":"Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the drug addiction treatment act of 2000 waiver","volume":"5","author":"Lanham","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209382_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109933","article-title":"Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016-2021","volume":"248","author":"Larochelle","year":"2023","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2024.209382_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.29245\/2578-2959\/2023\/1.1263","article-title":"Racial disparities in opioid use disorder and its treatment: A review and commentary on the literature","volume":"7","author":"Lynch","year":"2023","journal-title":"J Ment Health Clin Psychol."},{"key":"10.1016\/j.josat.2024.209382_bb0080","series-title":"Increased use of telehealth for OUD services during COVID-19 pandemic associated with reduced risk of overdose","author":"NIDA","year":"2022"},{"issue":"8","key":"10.1016\/j.josat.2024.209382_bb0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13456","article-title":"Association of pregnancy and insurance status with treatment access for opioid use disorder","volume":"3","author":"Patrick","year":"2020","journal-title":"JAMA Network Open"},{"issue":"9","key":"10.1016\/j.josat.2024.209382_bb0095","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.josat.2024.209382_bb0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.5734","article-title":"Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts","volume":"3","author":"Schiff","year":"2020","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1016\/j.josat.2024.209382_bb0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.5996","article-title":"Changes in US clinician waivers to prescribe buprenorphine management for opioid use disorder during the COVID-19 pandemic and after relaxation of training requirements","volume":"5","author":"Spetz","year":"2022","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2024.209382_bb0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.51856","article-title":"Trends and characteristics of buprenorphine-involved overdose deaths prior to and during the COVID-19 pandemic","volume":"6","author":"Tanz","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209382_bb0115","author":"The Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.josat.2024.209382_bb0120","article-title":"Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl","author":"Varshneya","year":"2021","journal-title":"Journal of Addiction Medicine"},{"issue":"8","key":"10.1016\/j.josat.2024.209382_bb0125","first-page":"42","article-title":"Accidental drug overdose deaths in Rhode Island: January 1, 2016-December 31, 2022","volume":"106","author":"Weidele","year":"2023","journal-title":"R.I. Medical Journal"},{"issue":"1","key":"10.1016\/j.josat.2024.209382_bb0130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0976-3147.91934","article-title":"Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds","volume":"3","author":"Whelan","year":"2012","journal-title":"J Neurosci Rural Pract."}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924000948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924000948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T06:25:53Z","timestamp":1717914353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875924000948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":27,"alternative-id":["S2949875924000948"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209382","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209382"}}